kidney and dialysis

an Open Access Journal by MDPI

Tracked for Impact Factor

Indexed in: Scopus

Expert Opinions on the (Hemo)dialysate Sodium Prescription

Guest Editors:

Dr. Manfred Hecking
Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Währinger Gürtel 18–20, 1090 Vienna, Austria

Prof. Dr. Peter Kotanko
1. Renal Research Institute, New York, NY, USA
2. Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Dr. Jochen G. Raimann
Renal Research Institute, New York, NY, USA

Deadline for manuscript submissions:
closed (31 March 2022)

Message from the Guest Editors

Numerous studies have attempted to help clinicians to prescribe the optimal sodium concentration in the dialysate bath of hemodialysis patients. However, studies on the associations between dialysate sodium concentrations and outcomes, such as intradialytic morbid events, cardiac morphology, cardiovascular disease, risk of hospitalizations and mortality, have been heavily debated. The scarcity of unconfounded insights from adequately powered randomized studies has complicated the conversation.

In anticipation of insights from adequately powered studies, this Special Issue aims to amalgamate the current opinions of experts in the field informing the community on how to approach this complex topic in their clinical practice.

Specific Aim: "*You are being put in charge as the Medical Director of a newly built dialysis clinic in your country. In consideration of available resources and reimbursement policies, how would you prescribe the dialysate sodium concentration for your patients? What would your approach be and why?*"

Please provide your opinion statement in no less than 500 words.

kidney and dialysis

Tracked for Impact Factor

Indexed in: Scopus

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Francesco Locatelli
Department of Nephrology and Dialysis, Alessando Manzoni Hospital, Lecco, Italy

Message from the Editor-in-Chief

In recent years, we have been witnessing dramatically increased interest in the treatment of chronic kidney disease, e.g., diabetic kidney disease, glomerular disease, or autosomal dominant polycystic kidney disease, but also aimed more generally on the progression of chronic kidney disease and the complications of chronic kidney disease, such as anemia, or hyperkalemia. This progress has led to changing paradigms as reflected by several recently published KDIGO guidelines which now need to be updated much more frequently than before. To personalize treatment, we also need better diagnostic methods, including validated biomarkers reflecting the activity of the disease (including response to treatment) and predicting outcomes.

Kidney and Dialysis aims to cover most of these areas not only in terms of feature reviews, but also original articles, and to keep the reader updated on recent progress in nephrology and dialysis.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within ESCI (Web of Science), Scopus and other databases.
Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 53.2 days after submission; acceptance to publication is undertaken in 5.9 days (median values for papers published in this journal in the first half of 2024).

Contact Us

Kidney and Dialysis Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/kidneydial
kidneydial@mdpi.com
𝕏@Kidneydial_MDPI